ENT (Otorhinolaryngology) in New Hampshire

The Prometheus Group® is a US-based medical device manufacturer with over 30 years of experience in diagnostic and therapeutic medical equipment. The company originated in pelvic floor rehabilitation and has evolved into a global developer and distributor of urodynamic systems, ultrasound technologies, and rehabilitation equipment. Primary product lines include the Morpheus® Urodynamics system with Office, Advanced, and Video configurations—designed for urology, pediatric urology, urogynecology, and colorectal surgery applications. The Morpheus® systems integrate uroflowmetry, voiding cystometry, video-compatible C-arm integration, transperineal ultrasound transducers, and EMG catheter channels with expandable architecture. The company also serves physical therapy and occupational therapy markets, plus speech-language pathology and dysphagia specialists. Manufacturing is US-based. The company holds ISO 13485 certification and MDSAP certification (valid through October 2028), indicating compliance with international quality management standards and multi-region regulatory frameworks. Products feature industrial-grade computing, hydraulic height-adjustable workstations, and curved UHD monitors for clinical data visualization. Technical support, customer service, and order management teams are domestic.

Rhinomed is a global medical device company specializing in wearable nasal technology for respiration, sleep, diagnosis of upper respiratory disease, and nasal drug delivery. The company manufactures diagnostic swabs (Rhinoswab and Rhinoswab Junior) designed for safe, comfortable, and reliable respiratory sample collection for COVID-19, influenza, RSV, and other upper respiratory pathogens. Rhinoswab Junior is specifically engineered for pediatric patients and has been validated in clinical studies demonstrating superior accuracy, comfort, and ease-of-use compared to traditional nasopharyngeal swabs. Beyond diagnostics, Rhinomed develops wearable devices for clinical applications including nasal stenting, breathing assistance for athletes (Turbine—designed to increase airflow up to 38%), and sleep enhancement (Mute—designed to dilate nasal passages to reduce snoring and mouth breathing). The company serves diagnostic laboratories, hospitals, sports medicine, sleep clinics, and government health agencies. Products are deployed globally with significant adoption in Australia and Europe. Rhinomed has secured major purchase orders from government health agencies (e.g., Victorian Department of Health) and distribution partnerships. The company maintains a pipeline of innovation focused on unmet clinical needs in nasal and respiratory health, including nasal drug delivery platforms and clinical stenting applications. Manufacturing and quality standards align with regulatory requirements for medical devices in key markets.